Pharmaceutical and biotechnology companies have always been the biggest buyers of analytical instruments — they need them for drug discovery, formulation, and QC. But hospitals and diagnostic laboratories are the fastest‑growing end‑user segment. The life science & analytical instruments market forecast shows that hospitals and diagnostic labs are growing at over 7% CAGR, driven by the shift to precision medicine and the need for in‑house testing.

What's driving this? Cancer diagnostics. Hospitals are buying next‑generation sequencers and mass spectrometers to run their own tumour profiling panels, rather than sending samples out. The life science & analytical instruments market analysis notes that the fastest‑growing instrument type is PCR (polymerase chain reaction), which saw a pandemic‑driven surge and is now standard in every hospital lab.

But hospitals face challenges: budget constraints, lack of trained personnel, and regulatory hurdles. That's why many partner with reference labs or use outsourced services.

The message: if you're a hospital administrator, investing in in‑house analytical capabilities can save money and speed up results. But it's not a decision to take lightly. Start with a few key instruments and scale up.